Description du projet DEENESFRITPL Une nouvelle technologie de microscopie pourrait accélérer le développement de médicaments Le projet SMIMS, financé par l’UE, veut démontrer le vaste potentiel de la microscopie à diffusion interférométrique pour la spectrométrie de masse de biomolécules individuelles en solution. Les chercheurs prévoient de produire un prototype commercialisable et de mettre en œuvre les modifications logicielles requises pour démontrer que la technologie est suffisamment robuste pour justifier un financement en capital-risque pour une entreprise dérivée. Cet instrument portable permettra des tests sur site sur un large éventail d’analytes et d’environnements potentiels. Une nouvelle technologie de microscopie largement accessible pourrait offrir de nouvelles opportunités pour le dépistage de candidats-médicaments potentiels et approfondir notre compréhension des interactions médicamenteuses au niveau moléculaire. Afficher les objectifs du projet Masquer les objectifs du projet Objectif We aim to demonstrate the disruptive commercial and societal potential of interferometric scattering microscopy for mass spectrometry of single biomolecules in solution. The PoC grant will be used to produce a near-market ready prototype and implement the required software modifications expected of a commercial device, to demonstrate that the technology is sufficiently robust to warrant venture capital funding for our spin-out company. Our early discussions with both pharma and instrument manufactueres have highlighted a need for more in-depth application of our technique. The novelty of our approach requires both demonstration and testing on a broad range of potential analytes and environments, which is why we require a portable instrument, that not only enables on-site testing, but also on-site demonstration in a non-university research environment. Similarly, there is a clear and pressing need to produce more intuitive and clearly commercially viable software to unlock the full potential of our technology. Data from these experiments will help define our final product(s) and to translate this research into a viable package for raising venture capital. The development of a novel, broadly accessible technology enables new avenues for screening potential drug candidates that could be used to further our understanding of drug interactions at the molecular level. The economic benefits will, therefore, be realised primarily through the pharmaceutical, healthcare and allied industries as well as the bioanalytical industry, through increased sales of instruments. All will have a considerable impact on the European economy. In addition to drug-discovery-related advances, our technology has the potential to transform cholesterol classification and change current approaches to cancer screening, through its intrinsic single molecule sensitivity. Champ scientifique medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverynatural sciencescomputer and information sciencessoftwarenatural sciencesbiological sciencesbiochemistrybiomoleculesnatural sciencesphysical sciencesopticsmicroscopynatural scienceschemical sciencesanalytical chemistrymass spectrometry Programme(s) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Thème(s) ERC-2018-PoC - ERC Proof of Concept Grant Appel à propositions ERC-2018-PoC Voir d’autres projets de cet appel Régime de financement ERC-POC - Proof of Concept Grant Institution d’accueil THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD Contribution nette de l'UE € 142 050,00 Adresse WELLINGTON SQUARE UNIVERSITY OFFICES OX1 2JD Oxford Royaume-Uni Voir sur la carte Région South East (England) Berkshire, Buckinghamshire and Oxfordshire Oxfordshire Type d’activité Higher or Secondary Education Establishments Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 142 050,00 Bénéficiaires (1) Trier par ordre alphabétique Trier par contribution nette de l'UE Tout développer Tout réduire THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD Royaume-Uni Contribution nette de l'UE € 142 050,00 Adresse WELLINGTON SQUARE UNIVERSITY OFFICES OX1 2JD Oxford Voir sur la carte Région South East (England) Berkshire, Buckinghamshire and Oxfordshire Oxfordshire Type d’activité Higher or Secondary Education Establishments Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 142 050,00
